7. Ohnishi T. The disaster at Japan’s Fukushima-Daiichi nuclear power plant after the March 11, 2011 earthquake and tsunami, and the resulting spread of radioisotope contamination. Radiat Res. 177(1):1-14, 2012

8. Okada H, Hontsu S, Miura S, Asakawa I, Tamamoto T, Katayama E, Iwasaki S, Kimura H, Kichikawa K, Hasegawa M. Changes of tumor size and tumor contrast enhancement during radiotherapy for non-small-cell lung cancer may be suggestive of treatment response. J Radiat Res. 53(2):326-32, 2012

9. Shirone N, Shinkai T, Yamane T, Uto F, Yoshimura H, Tamai H, Imai T, Inoue M, Kitano S, Kichikawa K, Hasegawa M. Axillary lymph node accumulation on FDG-PET/CT after influenza vaccination. Ann Nucl Med. 26(3):248-52, 2012

10. Kirita T, Yamanaka Y, Imai Y, Yamakawa N, Aoki K, Nakagawa Y, Yagyuu T, Hasegawa M. Preoperative concurrent chemoradiotherapy for stages II-IV oral squamous cell carcinoma: a retrospective analysis and the future possibility of this treatment strategy. Int J Oral Maxillofac Surg. 41(4):421-8, 2012

11. Tanaka N, Asakawa I, Fujimoto K, Anai S, Hirayama A, Hasegawa M, Konishi N, Hirao Y. Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer. BMC Urol. 12:28, 2012